Viatris (VTRS) Consolidated Net Income (2019 - 2026)
Viatris (VTRS) posted quarterly Consolidated Net Income of $176.4 million for Q1 2026, up 105.8% year-over-year from $85.7 million in Q1 2025, and up 151.87% quarter-over-quarter from -$340.1 million in Q4 2025.
Viatris (VTRS) Consolidated Net Income (2019 - 2026) Analysis & Trends
Viatris' Consolidated Net Income history runs 8 years deep, the most recent figure standing at $176.4 million for Q1 2026.
- In Q1 2026, Consolidated Net Income rose 105.8% year-over-year to $176.4 million; the TTM figure through Mar 2026 stood at -$296.5 million (up 92.18% YoY), while the FY2025 annual figure was -$3.5 billion, down 454.23% from the prior year.
- Consolidated Net Income for Q1 2026 stood at $176.4 million, up from -$340.1 million in the prior quarter.
- The five-year high for Consolidated Net Income was $1.0 billion in Q4 2022, with the low at -$3.0 billion in Q1 2025.
- The 5-year median for Consolidated Net Income is $113.9 million (2024), against an average of -$108.2 million.
- The sharpest annual moves came in 2022 and 2025: Consolidated Net Income soared 483.32% in 2022, then sank 2770.76% in 2025.
- Viatris' Consolidated Net Income stood at $1.0 billion in 2022, then tumbled by 175.71% to -$765.6 million in 2023, then soared by 32.54% to -$516.5 million in 2024, then soared by 34.15% to -$340.1 million in 2025, then soared by 151.87% to $176.4 million in 2026.
- Business Quant data shows VTRS's Consolidated Net Income at $176.4 million in Q1 2026, -$340.1 million in Q4 2025, and -$128.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.86 Bn | 42.90 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.54 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.79 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.57 Bn | 22.77 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.49 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.71 Bn | 11.18 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Alkermes | 8.09 Bn | 7.44 Bn | 397.90 Mn | 524,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -118.80 Mn |
| Mar 31, 2026 | 176.40 Mn |
| Dec 31, 2025 | -340.10 Mn |
| Sep 30, 2025 | -128.20 Mn |
| Jun 30, 2025 | -4.60 Mn |
| Mar 31, 2025 | -3.04 Bn |
| Dec 31, 2024 | -516.50 Mn |
| Sep 30, 2024 | 94.80 Mn |
| Jun 30, 2024 | -326.40 Mn |
| Mar 31, 2024 | 113.90 Mn |
| Dec 31, 2023 | -765.60 Mn |
| Sep 30, 2023 | 331.60 Mn |
| Jun 30, 2023 | 264.00 Mn |
| Mar 31, 2023 | 224.70 Mn |
| Dec 31, 2022 | 1.01 Bn |
| Sep 30, 2022 | 354.30 Mn |
| Jun 30, 2022 | 313.90 Mn |
| Mar 31, 2022 | 399.20 Mn |
| Dec 31, 2021 | -263.80 Mn |
| Sep 30, 2021 | 311.50 Mn |